Swissmedic: Taking its Own Path
Regarded as one of the world’s leading regulatory bodies, Swissmedic stands alongside its equivalents in Europe, Japan, Canada, and Australia in terms of the evaluation and approval of new drugs,…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Regarded as one of the world’s leading regulatory bodies, Swissmedic stands alongside its equivalents in Europe, Japan, Canada, and Australia in terms of the evaluation and approval of new drugs,…
Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of…
Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide, forming collaborations between entrepreneurs and the Johnson & Johnson Family of Companies’ global healthcare businesses. Michael Hübner, Early…
While once considered the land of milk and honey within Europe in terms of market access and reimbursement for innovative pharmaceuticals, Switzerland is increasingly tightening its belt on this front…
Stefan Berg, general manager of Pharmaplan, one of the leading pharma engineering partners in Europe, outlines the key trends in this area, including an expected investment boom in the coming…
Merck Switzerland’s Christiane von der Eltz highlights the German firm’s recent big investments in Switzerland and how it forms a key part of Merck’s global research and manufacturing networks. von…
Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique transcription factor targeting molecule potentially represents a breakthrough in…
The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based global behemoths, what value does Switzerland itself hold and what do they see as…
Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the…
Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to control appetite, and how it compares with the…
Interpharma’s Dr René P. Buholzer highlights the key lessons that Switzerland’s innovative pharmaceutical industry has taken from the COVID-19 pandemic, the challenges inherent in the country’s two upcoming cost containment…
AstraZeneca’s recently arrived Switzerland country president, Katrien de Vos, gives her first impressions of the Swiss market and how she hopes to build upon the affiliate’s strong performance. de Vos…
See our Cookie Privacy Policy Here
